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Vascular tumors occur in approximately 10% of all in-
fants and may be associated with signi¢cant morbidity.
Available therapies for vascular tumors, such as sys-
temic corticosteroids, vincristine, and interferon-a,
may cause toxicity, limiting their use to complicated
cases. Using a mouse hemangioendothelioma model,
we investigated the e⁄cacy and mechanism of action
of imiquimod, a topically applied inducer of cytokines.
Application of imiquimod cream, whether initiated at
the time of cell inoculation or when tumors became
visible, signi¢cantly decreased tumor growth and in-
creased animal survival in comparison with control
mice. Imiquimod-treated tumors showed decreased tu-
mor cell proliferation, increased tumor apoptosis, and
increased expression of tissue inhibitor of matrix metal-
loproteinase-1 with decreased activity of matrix metal-
loproteinase-9.The demonstration that local application
of imiquimod inhibits vascular tumor enlargement in
the mouse vascular tumor model suggests a novel, less
toxic means of treating infantile hemangioendothelio-
mas and perhaps other cutaneous vascular tumors. Key
words: cytokines/hemangioendothelioma/neoplasm. J Invest
Dermatol 121:1205 ^1209, 2003
V
ascular tumors are the most common benign neo-
plasms of infancy, occurring in approximately 10%
of infants (Drolet et al, 1999). Hemangiomas of in-
fancy are most common, and cause serious compli-
cations in 5 to 10% of patients. Other vascular
tumors, particularly hemangioendotheliomas and tufted angio-
mas, have been associated with the Kasabach^Merritt syndrome
in infancy (Teillac-Hamel et al, 1993; Enjolras et al, 1997), charac-
terized by rapid tumor growth and coagulopathy. The few e¡ec-
tive medical therapies for vascular tumors, namely corticosteroids,
interferon-a (Ezekowitz et al, 1992), and vincristine (Schirner et al,
1998), all require systemic administration and have been asso-
ciated with potential toxicity (Soumekh et al, 1996; Barlow et al,
1998).
Although the pathomechanism of infantile vascular tumors is
unknown, the rapid proliferation of endothelial cells (Boye et al,
2001) suggests the importance of angiogenesis. In fact, angiogenic
factors, such as vascular endothelial growth factor, basic ¢broblas-
tic growth factor (Takahashi et al, 1994), and insulin-like growth
factor-2 (Ritter et al, 2002) are overexpressed during the prolif-
eration of hemangiomas, whereas the anti-angiogenic factor tis-
sue inhibitor of matrix metalloproteinase (TIMP) 1 is expressed
during involution (Takahashi et al, 1994). Involuting tumors also
show a marked decrease in expression of markers of proliferation,
such as proliferating cell nuclear antigen (PCNA) and Ki-67
(Mancini and Smoller, 1996), and an increase in cell apoptosis
(Razon et al, 1998).
During the past decade, our understanding of angiogenesis
and the role of cytokines in tumor biology has blossomed, lead-
ing to the availability of novel agents that slow the growth of
tumors, many with minimal or no known toxicity. Although
no good mouse model of hemangioma exists, mouse heman-
gioendothelioma models have shown the e⁄cacy of anti-angio-
genic medications and inducers of cytokine production in
inhibiting vascular tumor proliferation (Taraboletti et al, 1995;
Lannutti et al, 1997;Wang et al, 1999;Vergani et al, 2001).
Imiquimod 5% cream is a commercially available cream that
has been used to treat viral-induced and neoplastic proliferative
disorders of keratinocytes (Edwards, 2000; Skinner et al, 2000;
Barba et al, 2001). Local dermatitis has been the only signi¢cant
side-e¡ect. Topical application of imiquimod to mouse and hu-
man skin elicits the local production from keratinocytes and
monocytes of cytokines (for reviews see Imbertson et al, 1998;
Sauder, 2000). We postulated that application of topical imiqui-
mod would slow or prevent vascular tumor growth. The poten-
tial advantages to topical therapy with imiquimod would be
several: (1) an improved safety pro¢le as local production of cyto-
kines theoretically decreases the potential for systemic adverse
events; (2) ease of topical administration; (3) decreased cost com-
pared with systemically administered therapies; and (4) the poten-
tial for use as an adjunctive agent for more complicated vascular
tumors. Using a mouse vascular tumor model, we have shown
that topical application of imiquimod cream inhibits heman-
gioendothelioma proliferation and induces cell apoptosis.
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MATERIALS AND METHODS
Murine tumor model All studies were approved by the Institutional
Animal Care and Use Committee of the Children’s Memorial Institute for
Education and Research. A mouse hemangioendothelioma model was
generated by inoculation of EOMA cells, as we have previously described
(Lannutti et al, 1997;Wang et al, 1999). The EOMA hemangioendothelioma
cell line used in this model arose spontaneously in a 129/J mouse, providing
an immunocompetent mouse model that is capable of responding to a
cytokine inducer (Hoak et al, 1971; Obeso et al, 1990). Tumors are ¢rst
visible approximately 5 d after inoculation of tumor cells, leading to
death at an average of 16 d after inoculation from tumor burden and the
associated bleeding diathesis that simulates Kasabach^Merritt syndrome of
infancy (Lannutti et al, 1997). Female 129/J mice (Jackson Laboratories, Bar
Harbor, Maine) were obtained at 6 wk of age. EOMA cells (courtesy of Dr
Robert Auerbach, Madison, Wisconsin) were maintained in Dulbecco’s
modi¢ed essential medium supplemented with 10% fetal bovine serum
and antibiotics. Mice were injected subcutaneously in the right £ank with
106 EOMA cells, and tumor growth was measured every other day by
tissue calipers. Tumor volume was determined as (width)2 length. Mice
were weighed and photographed every other day. Except for survival
experiments, mice were euthanized at 17 d after tumor cell inoculation
when control mice began to develop lethargy and pallor. Each
experiment was performed with at least four mice for each condition
studied, and studies were repeated two to six times.
Imiquimod applications One ¢ngertip unit (200 mg per ¢ngertip unit;
Long and Finlay, 1991) of imiquimod 5% cream (3M Pharmaceuticals, St
Paul, Minnesota) was applied to the £ank at the site of EOMA cell
inoculation three times weekly to two treatment groups. In one group,
imiquimod was applied starting on the day of EOMA cell inoculation (I1)
to assess the ability of imiquimod to prevent or slow initial tumor growth.
In a separate study group, imiquimod was applied beginning on day 5 (I5)
after EOMA cell inoculation to assess its ability to alter growth of an
established tumor. Control mice were treated beginning on day 1 (vehicle
base 1, B1) or day 5 (vehicle base 5, B5) with one ¢ngertip unit of the cream
vehicle three times weekly as a control. In addition to a vehicle control,
20% arachidonic acid (Sigma, St Louis, Missouri) in acetone was applied
three times weekly to the tumoral site beginning at day 1 (A1) to create
local skin in£ammation by a mechanism that involves neutrophil
in¢ltration but not T lymphocyte cytokine release as previously described
(Doherty et al, 1988). Given the potential systemic absorption of imiquimod
ingestion by self-preening or preening by other mice, mice for these
studies were ¢tted with a soft, foam collar for 2 h after application of the
topical agents and mice were housed separately.
Survival studies Survival to a pre-terminal state was compared among
treatment groups (vehicle base control, arachidonic acid control, and the
imiquimod) with three times weekly application beginning on the date of
inoculation.
Tissue harvesting Mice were anesthetized with nembutal 2 h after their
last treatment. Tissue was obtained from the tumor plus skin overlying the
tumor and from distant untreated skin. Skin samples were dipped in
phosphate-bu¡ered saline pH 7.4 prior to processing to remove residual
topical medication. In approximately half of the mice, the tissue was
bisected. One-half was placed in 10% formaldehyde for para⁄n
embedding and the other half embedded in O.C.T. and stored at ^201C.
Tumor samples for analysis of PCNA, matrix metalloproteinase (MMP)-
9, and TIMP-1 were weighed, rinsed in phosphate-bu¡ered saline, snap
frozen in liquid nitrogen, and stored at ^701C.
Immunohistochemistry Studies of apoptosis were conducted as
previously described (Lannutti et al, 1997; Wang et al, 1999), using a
Klenow FragEL DNA fragmentation detection kit (Oncogene,
Cambridge, Massachusetts). Tumor cell proliferation was assessed as pre-
viously described (Lannutti et al, 1997; Wang et al, 1999) with anti-PCNA
antibody (DAKO, Carpenteria, California), and detected using colori-
metric techniques following the manufacturer’s instructions (Vectastain
Elite ABC Kit,Vector Laboratories, Inc., Burlingame, California).
Immunoblotting Tumor tissue from imiquimod-treated and vehicle
control-treated mice was either homogenized in bu¡er containing 50 mM
Tris pH 7.5, 137 mM NaCl, and 10% sodium dodecyl sulfate (SDS) or
incubated for studies of MMP-9 in Dulbecco’s modi¢ed essential medium
containing 6% bovine serum albumin for 48 h at 371C. Protein
concentration was measured by a modi¢ed Bradford assay (Coomassie
Plus Protein Assay, Pierce, Rockford, Illinois). Equal amounts of total
protein from either whole tissue lysates for TIMP-1 and PCNA expression
or concentrated tissue culture supernatant for MMP-9 expression were
boiled in Laemmli sample bu¡er (Laemmli, 1970) for 10 min and
separated on 8 to 12% SDS^polyacrylamide gel electrophoresis mini-gels.
After electrophoresis, separated protein was transferred to nitrocellulose
membrane (Bio-Rad, Hercules, California), and nonspeci¢c binding was
blocked by incubation for 1 h with 5% dry milk in 50 mM Tris^HCl, pH
7.6 with 137 mM NaCl, and 0.1% Tween-20. Lanes were treated with 500
ng anti-TIMP-1 monoclonal antibody per mL (Calbiochem, La Jolla,
California), 200 ng anti-PCNA monoclonal antibody per mL, or 2 mg anti-
MMP-9 antibody per mL for 1 h, and immunoreactive bands detected
with peroxidase-conjugated goat anti-rabbit antibodies and enhanced
chemiluminescence (ECL kit, Amersham Pharmacia, Piscataway, New
Jersey) following manufacturer’s instructions. Bands were visualized on
Kodak X-Omat ¢lm after a 10 to 30 s exposure at room temperature.
Immunoblotted samples were tested in triplicate.
Gelatin zymography The e¡ect of imiquimod treatment on MMP-9
and MMP-2 activities was analyzed by gelatin zymography (Heussen and
Dowdle, 1980). In brief, tumor tissue from imiquimod-treated and vehicle
control-treated mice was incubated in Dulbecco’s modi¢ed essential
medium containing 6 mg bovine serum albumin per mL for 48 h at
371C. Fifty micrograms of protein from concentrated tissue culture
supernatant was treated with nondenatured sample bu¡er (17.4% SDS,
7% sucrose, and 0.01% phenol red) for 30 min at 251C and separated on
8% SDS^polyacrylamide gel electrophoresis mini-gels containing 0.1%
(w/v) gelatin. Following electrophoresis, gels were washed with 2.5%
Triton X-100 for 30 min at 371C to remove the SDS. Gels were incubated
at 371C overnight in developing bu¡er containing 50 mM Tris^HCl, pH
8.0, 100 mM NaCl, 5 mM CaCl2, and 5 mM ZnCl2. Gels were then stained
with 0.5% Coomassie Brilliant Blue R250 in 30% methanol and 7.5%
glacial acetic acid for 30 min and destained. Gelatin-degrading enzymes
were identi¢ed as clear bands against the blue background of the stained
gel. Images of stained gels were captured by the AlphaImager 2200 (San
Leandro, California). The intensity of the bands was measured by
densitometric analysis by Storm 800 £uorescence PhosphorImager
(Molecular Dynamics, Inc., Sunnyvale, California) and comparisons were
made within each gel to determine relative changes in MMP activity. Data
for each zymograph were expressed as relative changes in MMP activity
within the gel and in comparison with other zymographs. Each
experiment was repeated at least four times.
Statistical analysis Results are presented as mean7SD. Di¡erences
within treatment groups, for example, between application of imiquimod
at day 1 versus application of imiquimod at day 5, were analyzed using the
two-tailed Student’s t test. A Duncan’s multiple range test was applied to
determine di¡erences among all treatment groups on each day. p values
less than 0.05 were considered signi¢cant.
RESULTS
Tumor growth in imiquimod-treated mice Mice treated
with imiquimod beginning on day 1 (I1; n¼ 25) had tumors
that grew slowly, and achieved a tumor volume of 0.6870.47
cm3 by 17 d after tumor cell inoculation (Figs 1 and 2a,c). Mice
treated with imiquimod beginning on day 5 (I5; n¼11) showed
abrupt £attening of tumor growth curves, with more indolent
subsequent growth to a mean tumor volume of 0.7570.46 cm3
at 17 d after inoculation (Fig 1). In contrast, control mice treated
with the vehicle base, whether initiated on day 1 (B1; n¼17) or
day 5 (B5; n¼11), displayed rapid tumor growth to a mean
volume of 2.9371.44 cm3 and 2.4270.95 cm3, respectively, by 17
d after tumor cell inoculation (Figs 1 and 2b,d). The control mice
treated with arachidonic acid topically (n¼ 6) showed a mean
tumor volume of 4.32 cm371.35 after 17 d (Fig 1).
The di¡erences between tumor volumes of imiquimod-treated
tumors and arachidonic acid-treated tumors were statistically
signi¢cant at all time points (po0.01, Fig 1). Similarly, treatment
group B1 tumor volume was signi¢cantly greater than either
imiquimod treatment group (I1 and I5) at all time points
(po0.01 by day 17). Treatment group B5 tumor volume was
signi¢cantly greater than the I1 imiquimod treatment group at
all time points and signi¢cantly greater than the I5 imiquimod
treatment group by day 13 (po0.01). The tumor volume for the
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I5 imiquimod treatment group was not signi¢cantly greater than
that of the I1 imiquimod treatment group beyond 9 d after tumor
inoculation. No signi¢cant di¡erences were noted between the
arachidonic acid-treated and vehicle base-treated control arms,
except transiently between B5 and arachidonic acid at day 15.
No statistically signi¢cant di¡erences between B1 and B5 were
detected.
In contrast to vehicle-treated control mice (Fig 2b,d), mice
treated with imiquimod developed scaling and moderate
in£ammation of the treated tumoral and peritumoral area by
one to two applications (Fig 2a), which improved spontaneously
throughout the treatment period but never cleared entirely
(Fig 2c). Control tumors treated with arachidonic acid also
developed cutaneous in£ammation characterized by scaling and
erythema. Erosion or ulceration at the tumor site was not
observed in any mouse. Neither imiquimod-treated mice nor
control mice exhibited weight loss.
Mouse survival Vehicle and 20% arachidonic acid control
animals (n¼ 8 in each group) survived an average of 1671.7 d
and 1471.5 d, respectively, after inoculation, whereas imiquimod-
treated animals (n¼ 8) survived an average of 2472.1 d (po0.05)
(Fig 3). Survival of control mice treated with 20% arachidonic
acid was not statistically di¡erent from that of vehicle-treated
controls.
Mechanisms of growth inhibition E¡ect of imiquimod
treatment on cell proliferation, apoptosis, and TIMP-1 ex-
pression in the mouse model: To address the role of inhibition
of proliferation, PCNA expression was assessed by both
immunohistochemistry and immunoblot assays. PCNA staining
of tumor tissue revealed an approximately 10-fold decrease in the
number of cells stained in skin sections from mice treated with
imiquimod relative to skin sections from vehicle-treated mice.
Vehicle-treated controls (beginning on day 1) had an average of
24.872.39 PCNA-positive cells per high power ¢eld versus
2.271.1 PCNA-positive cells per high power ¢eld in mice
treated with imiquimod beginning on day 1 (not shown).
Topically applied imiquimod also markedly decreased the
expression of PCNA by nearly 20-fold based on densitometric
analysis of bands on immunoblots (Fig 4). To consider the role
of imiquimod-induced cell apoptosis in limiting tumor growth,
immunohistochemical analysis of caspase 3 expression was
performed. Apoptosis was dramatically increased in the tumor
tissue of imiquimod-treated tissue relative to controls. In
imiquimod-treated tumors, 38.6712.2 apoptotic cells were
detected per high power ¢eld (Fig 5a); in vehicle base treated
tumors, 2.8371.9 cells per high power ¢eld were observed
(Fig 5b). TIMP-1 expression was evaluated as a marker of
vascular tumor cell involution and because of its inhibitory
e¡ect on MMP-9 activity, which promotes tumor expansion.
TIMP-1 expression was increased nearly 14-fold in mice treated
with imiquimod (n¼ 4) versus vehicle controls (n¼ 4) (Fig 6a).
Figure1. Imiquimod inhibits tumor growth. Mice were treated with
imiquimod cream three times weekly beginning on day 1 (I1) or day 5 (I5)
after tumor cell inoculation, vehicle base beginning on day 1 (B1) or day 5
(B5) after inoculation, or with 20% arachidonic acid beginning day 1 (A1)
after inoculation. Tumors were measured every other day once visible and
tumor volumes calculated. Error bars represent mean7SD. I, imiquimod;
B, vehicle base; A, arachidonic acid.
Figure 2. Topical application of imiquimod inhibits tumor growth
in 129/J mice.Tumors were photographed serially every 4 d to record the
appearance of the tumors and the potential irritant dermatitis. Mice treated
with imiquimod beginning day 1 at 9 d (a) and 17 d (c) after EOMA cell
introduction. Mice treated with vehicle base beginning on day 1 at 9 d (b)
and 17 d (d) after EOMA cell introduction.
Figure 3. Imiquimod application to mouse tumors increases mouse survi-
val. Imiquimod, or as a control the vehicle base or arachidonic acid, was
applied three times weekly beginning on day 1 to tumors.
Figure 4. Imiquimod treatment inhibits tumor PCNA expression.
PCNA expression was analyzed by immunohistochemistry using anti-
mouse PCNA monoclonal antibody. I1-I4 are samples extracted from four
EOMA cell tumors treated with imiquimod beginning on day 1; B1^4 are
samples extracted from four tumors treated with vehicle base.
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Imiquimod had no e¡ect on the expression of MMP-9 (Fig 6b,
top row), but decreased MMP-9 activity by 3.2- to 5.1-fold (Fig
6b, middle row). Imiquimod application had no e¡ect on MMP-
2 activity (Fig 6b, bottom row).
DISCUSSION
Using a mouse hemangioendothelioma model, we have provided
evidence that topical application of imiquimod, a commercially
available cream, inhibits the growth of the vascular tumors and
promotes tumor apoptosis. Our data with this topical agent com-
pare favorably with results obtained using the same mouse model
with other anti-angiogenic agents administered systemically or
by gene therapy. Using the EOMA mouse model, Lannutti et al
(1997) noted a dramatic reduction in tumor growth and an in-
crease in mouse survival after twice daily subcutaneous adminis-
tration of angiostatin puri¢ed from human plasma. The
mechanism of angiostatin’s action involved the induction of the
endothelial cell apoptosis without observed toxicity. Wang et al
(1999) introduced mouse interleukin-12 cDNA by gene gun into
the epidermis overlying the EOMA tumor at peritumoral sites
every other day for 1wk. The inhibition of tumor growth corre-
lated with increased epidermal expression of interleukin-12, and
increased local levels of both interferon-g and tumor necrosis fac-
tor-a, which have shown synergy in their cytoxic e¡ects on
EOMA cells in vitro (Lannutti et al, 1997). Similar to the e¡ect of
angiostatin, a local increase in cytokine levels caused EOMA cell
apoptosis. Although all of these agents successfully slowed the
growth of the endothelial cell tumors, these therapeutic
approaches are unavailable for clinical application, especially in
pediatric patients.
The mechanism of the imiquimod-induced inhibition of
mouse hemangioendothelioma growth involves both inhibition
of proliferation and increase in tumor cell apoptosis, changes seen
in the natural involution of the more common vascular tumor
hemangioma of infancy (Razon et al, 1998). The increase in
TIMP-1 expression caused by topical application of imiquimod
cream also mirrors that seen in hemangiomas undergoing involu-
tion spontaneously or induced by systemic therapy (Takahashi
et al, 1994; Hasan et al, 2000). TIMP-1, a known inhibitor of an-
giogenesis (Johnson et al, 1994) and cell motility, has been shown
to attenuate tumor growth when overexpressed (Bloomston et al,
2002). Using eEND.1 transformed endothelioma tumors in nude
mice, Taraboletti et al (1995) showed the e⁄cacy of daily intratu-
moral injections of the MMP inhibitor batimastat in slowing
tumor growth. Most recently, Vergani et al (2001) used retro-
virus-mediated gene transfer to introduce TIMP-2 into eEND.1
cells, resulting in slowed tumor growth when transfected cells
were inoculated into nude mouse skin by reducing the recruit-
ment of host endothelial cells. Consistent with the increase in
TIMP-1 expression, MMP-9 activity was decreased, which may
have led to decreased local tumor invasivity.
The safety of topical administration of imiquimod is of para-
mount importance prior to administration to infants with he-
mangioendotheliomas and other vascular tumors. In this study
in mice, the only observed toxicity of topical imiquimod was that
described in human studies, i.e., local irritation at the treatment
site. Erythema and scaling developed after 3 to 4 d of therapy
(one to two applications), but improved spontaneously despite
continued treatment (Fig 2a,c). To address the signi¢cance of this
irritation in inhibiting tumor growth, we compared imiquimod-
treated mice with mice treated with an application of 20% ara-
chidonic acid, which is known to trigger skin in£ammation by
a mechanism that involves neutrophils but not T lymphocyte cy-
tokine release (Doherty et al, 1988). Despite induction of in£am-
mation in the skin overlying the tumor, animals treated with
20% arachidonic acid topically three times a week showed tumor
growth slightly greater than controls.
Preliminary data suggest the e⁄cacy and safety of application
of imiquimod in two infants with hemangiomas (Martinez et al,
2002). Our studies further support the use of topical imiquimod
as novel immunomodulatory therapy for hemangioendothelio-
mas and perhaps hemangiomas of infancy, most of which are cur-
rently left untreated due to potential toxicities of available
therapies.
These investigator-initiated studies were funded by grants from the March of Dimes,
the Dermatology Foundation, the Unilever Endowment and the Chicago Dermatolo-
gical Society. The imiquimod cream and vehicle control base were provided by 3M
Pharmaceuticals.
Figure 5. Imiquimod application triggers vascular tumor cell apop-
tosis. Tumors from mice treated with imiquimod (a) or vehicle base (b)
were evaluated for apoptotic cells by immunohistochemical staining with
a Klenow FragEL DNA fragmentation detection kit. Bar¼ 50 mm.
Figure 6. Imiquimod treatment decreases MMP-9 activity through
enhancement of TIMP-1 expression.Tumor tissue of mice treated with
imiquimod (I) or vehicle base (B) was either treated with lysis bu¡er to
extract total protein for TIMP-1 and MMP-9, or incubated in serum-free
Dulbecco’s modi¢ed essential medium to analyze MMP-9 and MMP-2 ac-
tivities as described in Materials and Methods. TIMP-1 expression was de-
tected using anti-mouse TIMP-1 monoclonal antibody (a). MMP-9
expression was detected with anti-mouse MMP-9 antibody (b, top row).
MMP-9 and MMP-2 activities were determined by zymography using
gelatin as a substrate (b, middle and bottom rows, respectively).
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